Peter Schmid
Impact in
- Oncology top 10%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cancer-related Molecular Pathways
-
- Advanced Breast Cancer Therapies
Papers in
- Oncology 7
- HER2/EGFR in Cancer Research 6
- Cancer Treatment and Pharmacology 3
- Cancer Immunotherapy and Biomarkers 2
- Lung Cancer Research Studies 1
-
- Advanced Breast Cancer Therapies 6
- Co-authors
- Javier Cortés (8 shared papers)Komal Jhaveri (3 shared papers)Florence Dalenc (2 shared papers)Monica Motwani (2 shared papers)Sara M. Tolaney (4 shared papers)Delphine Loirat (3 shared papers)Eva Ciruelos (2 shared papers)Olivier Trédan (2 shared papers)
- Journals
- Cancer Research (8 papers)JNCI Journal of the National Cancer Institute (1 paper)The Lancet (1 paper)Breast Cancer Research (1 paper)
- Partner nations
- United KingdomUnited StatesSpain
In The Last Decade
Peter Schmid
11 papers receiving 305 citations
Peter Schmid's Hit Papers
Peers
Comparison fields: 5 of 35
- Oncology 209
- Pulmonary and Respiratory Medicine 90
- Cancer Research 35
- Radiology, Nuclear Medicine and Imaging 53
- Genetics 14
Countries citing papers authored by Peter Schmid
This map shows the geographic impact of Peter Schmid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Schmid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Schmid more than expected).
Fields of papers citing papers by Peter Schmid
This network shows the impact of papers produced by Peter Schmid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Schmid. The network helps show where Peter Schmid may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Schmid, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2023 | 242 |
| 2 | 2023 | 18 | |
| 3 | 2024 | 13 | |
| 4 | 2024 | 7 | |
| 5 | 2025 | 5 | |
| 6 | 2023 | 5 | |
| 7 | 2023 | 4 | |
| 8 | 2023 | 4 | |
| 9 | 2023 | 3 | |
| 10 | 2023 | 3 | |
| 11 | 2023 | 2 |
About Peter Schmid
Peter Schmid is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging and Genetics, having authored 11 papers that have together received 306 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (6 papers), Advanced Breast Cancer Therapies (6 papers), Breast Cancer Treatment Studies (3 papers), Cancer Treatment and Pharmacology (3 papers), Cancer Immunotherapy and Biomarkers (2 papers), Lung Cancer Research Studies (1 paper), Cancer Genomics and Diagnostics (1 paper) and BRCA gene mutations in cancer (1 paper). The work is most often cited by research in Oncology (209 citations), Pulmonary and Respiratory Medicine (90 citations), Cancer Research (35 citations), Radiology, Nuclear Medicine and Imaging (53 citations) and Genetics (14 citations). Peter Schmid has collaborated with scholars based in United Kingdom, United States and Spain. Frequent co-authors include Javier Cortés, Komal Jhaveri, Florence Dalenc, Monica Motwani, Sara M. Tolaney, Delphine Loirat, Eva Ciruelos, Olivier Trédan, Oh Kyu Yoon and Frederik Marmé. Their work appears in journals such as Cancer Research, JNCI Journal of the National Cancer Institute, The Lancet and Breast Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.